Učitavanje...
Management of Immune Checkpoint Inhibitor Toxicities
Immune checkpoint inhibitors (ICIs) have radically changed the clinical outcome of several cancers with durable responses. CTLA-4 (cytotoxic T lymphocyte antigen-4), PD-1 (programmed cell death protein 1) or PDL-1 (programmed cell death ligand protein 1) represent ICIs that can be used as monotherap...
Spremljeno u:
| Izdano u: | Cancer Manag Res |
|---|---|
| Glavni autori: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7533913/ https://ncbi.nlm.nih.gov/pubmed/33061607 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S218756 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|